Biomarkers and Efficacy of T-DM1/P in HER2 Breast Cancer Study

Core Concepts

The study focuses on analyzing biomarkers and the efficacy of T-DM1/P in HER2 breast cancer treatment.

Abstract

Authors and Disclosures:

• Authors from various institutions contributed to the study.
• Correspondence with the lead author provided.
  Author Contributions:
• Detailed breakdown of each author's contributions.
  Competing interests:
• Authors disclose their competing interests.

Stats

SLdH is an employee of, and owns stock in, Roche.
DJS owns stock in Pfizer, Amgen, Merck, Vertex, and Seattle Genetics; has received consulting fees from Novartis and Pfizer and research funding from Bayer and Novartis; and is a co-founder of 1200Pharma and TORL BioTherapeutics.
MM has served as a consultant for F. Hoffmann-La Roche, Genentech, Novartis, and AstraZeneca.
MFP has received research grants to his institution from Cepheid, Eli Lilly & Company, Novartis Pharmaceuticals, F. Hoffmann-La Roche Ltd, and Puma; has served as a consultant or advisor with honoraria for AstraZeneca, Biocartis SA, Cepheid, Eli Lilly & Company, Merck & Co, Puma Biotechnology, and Zymeworks Inc; has provided expert testimony for Amgen, Inc; and has private equity in TORL Biotherapeutics, LLA.
GLP is an employee of Genentech and owns stock in Roche.
CL is an employee of Roche.
AP owns stock in Reveal Genomics; has received honoraria from Pfizer, Novartis, Roche, MSD Oncology, Lilly, Daiichi Sankyo, Amgen, and Guardant Health; has served as a consultant or advisor for Amgen, Roche, Novartis, Pfizer, Bristol-Myers Squibb, Boehringer, PUMA, Oncolytics Biotech, Daiichi Sankyo, AbbVie, AstraZeneca, and NanoString Technologies; has received research funding from Roche, Novartis, Incyte, and Puma Biotechnology; and has received royalties for patents/other intellectual property for PCT/EP2016/080056 (HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy), WO/2018/096191 (chemoendocrine score [CES] based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence), HER2DX filing, and US 63/023785 (methods for breast cancer treatment and prediction of therapeutic response.
VL-V is an employee of, and owns stock in, Roche.
TB is an employee from Parexel International GmbH contracted by F. Hoffmann-La Roche for statistical services in the conduct of the study.
SAH has received travel support from F. Hoffmann-La Roche, Boehringer Ingelheim, Novartis, Lilly, Pfizer, and Bayer. Her institution has received research funding from Ambrx, AstraZeneca, Arvinas, Daiichi Sankyo, Dantari, G1-Therapeutics, Gilead, Immunomedics, MacroGenics, Pieris, Radius, Seattle Genetics, Zymeworks, Cytomx, Phoenix Molecular Designs, Ltd, F. Hoffmann-La Roche, Genentech, Novartis, GlaxoSmithKline, Boehringer Ingelheim, Sanofi, Pfizer, Amgen, OBI Pharma, Puma Biotechnology, Dignitana, Bayer, BioMarin, Lilly, and Merrimack.

Quotes

"All authors read and approved the final manuscript."

Key Insights Distilled From

Biomarkers and Efficacy of T-DM1/P in HER2 Breast Cancer

by Sanne L. De ... at www.medscape.com 04-06-2023

http://www.medscape.com/viewarticle/989760

Deeper Inquiries

How do competing interests impact the validity of medical research?

Competing interests in medical research can potentially bias the outcomes or interpretation of the study results. When authors have financial ties to pharmaceutical companies, there is a risk that their objectivity may be compromised. This can lead to a skewed presentation of data or a focus on results that align with the interests of the company rather than the scientific truth. Disclosure of these competing interests is crucial for transparency and allows readers to assess the potential impact on the validity of the research findings.

What are the implications of authors owning stock in pharmaceutical companies?

Authors owning stock in pharmaceutical companies can raise concerns about conflicts of interest. This financial stake may create a bias towards promoting the products or interventions of the company in which they hold stock. It could influence the study design, data analysis, interpretation of results, and even the conclusions drawn from the research. Transparency about these financial relationships is essential to maintain the credibility and trustworthiness of the research findings.

How can biomarker studies like this contribute to personalized medicine beyond breast cancer treatment?

Biomarker studies play a crucial role in advancing personalized medicine by identifying specific characteristics or markers that can predict treatment response or prognosis in individual patients. Beyond breast cancer treatment, the findings from biomarker studies can be extrapolated to other types of cancer or even non-cancer diseases. By understanding the genetic or molecular profiles that influence disease progression and response to therapy, healthcare providers can tailor treatment strategies to each patient's unique characteristics. This approach can lead to more effective and targeted interventions, minimizing adverse effects and optimizing outcomes across various medical conditions.